Volume 15, Number 3—March 2009
Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests
|Evaluation panel||No. samples|
|DENV IgM positive|
|From primary infections||27|
|From secondary infections||154|
|DENV IgM negative|
|DENV positive/DENV IgM negative||19|
|DENV IgG positive
|Related flavivirus IgM positive|
|West Nile virus positive||25|
|Yellow fever virus positive
|Related flavivirus IgG positive|
|West Nile virus positive||1|
|Yellow fever virus positive||10|
|St. Louis encephalitis virus positive||2|
|Japanese encephalitis virus positive
|Lyme disease IgG positive||9|
|New World hantavirus IgM positive
|Systemic lupus erythematosus
*DENV, dengue virus; Ig, immunoglobulin.
†No. serum samples identified as serotype specific: 26 DENV-1, 19 DENV-2, 13 DENV-3, and 7 DENV-4. Serotype was not identified for 116 samples.
‡From areas where dengue is not endemic.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.